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Summary 
Mice homozygous for the Ipr gene develop autoantibodies and polyclonal B cell activation similar 
to what is seen in human systemic lupus erythematosus patients.  We have previously shown 
that an lpr-specific  intrinsic B cell defect was necessary for autoantibody production in this model. 
In the current study, we have further defined these autoantibody-producing B cells. Two major 
subsets of B cells have been described.  B-1 cells (CD5 + B cells) can be distinguished from 
conventional B cells on the basis of phenotype, cytokine secretion, gene expression, anatomical 
location, and function. In addition, B-1 cells have been implicated in autoimmunity in several 
routine and human studies. To address the question of which B cell subset produces autoantibodies 
in Ipr mice, we used immunoglobulin heavy chain (Igh) allotype-marked  peritoneal  (B-1 cell 
source) and bone marrow (conventional B cell source) cells from lpr mice to establish B cell chimeras. 
We used two general approaches. In one, we reconstituted sublethally irradiated mice with B-1 
ceils of one allotype and bone marrow cells of another aliotype. In the second method, we suppressed 
endogenous B cells in neonatal mice with allotTpe-specific  anti-IgM antibody, and injected peritoneal 
ceils of another aI1otype. After antibody treatment was stopped,  the mouse's conventional  B 
cells recovered, but the B-1 subset was only reconstituted by the donor. In both types of chimeras, 
antichromatin, rheumatoid factor, and anti-single stranded DNA (ssDNA) autoantibodies were 
produced by the conventional B cell bone marrow source. In addition, an age-related decrease 
in peritoneal B-1 cells was seen, even in unmanipnlated lpr mice. These data show that lpr B-1 
cells are not important producers  of autoantibodies.  Conventional B cells are the source of 
autoantibodies  directed at chromatin, ssDNA, and IgG. 
D 
istinct subsets of B cells are recognized on the basis of 
function and cell surface phenotype (1). Those B cells 
initially characterized by their surface expression of the CD5 
antigen, provisionally called B-1 calls (2), have recently re- 
ceived attention as important autoantibody-producing cells 
in several human and murine experimental models 0). Call 
transfer studies using fetal omentum have shown indepen- 
dent development of B-1 and conventional B cells consistent 
with separate lineages (4), although other evidence suggests 
some ongoing interchange between the B-1 and conventional 
subsets based on phenotypic markers (5). In addition, B-1 
cells can be distinguished from conventional B cells by ana- 
tomical localization,  gene usage, function, and phenotype 
(3). B-1 cells are most prominent early in ontogeny and have 
a restricted tissue distribution and cellular origin (6-10). The 
antibodies  produced by B-1 cells are generally of the IgM 
isotype, lack somatic mutation, and have few to no N regions 
(3, 11-15). Their frequent reactivity with the autoantigens 
single  stranded  (ss)  1 DNA,  bromelain-treated  mouse red 
blood cells (BrMRBC), and autologous IgG has raised the 
possibility that autoantibody production in systemic autoim- 
munity is mainly due to the B-1 cells (16, 17). In support 
of this notion, it has been reported that B-1 cells are pri- 
marily responsible for the production of KF and polyreac- 
tire autoantibodies (13, 14, 17). Some autoimmune mice, such 
as motheaten, NZB, and related strains, have elevated levels 
of this subset (11, 13), and several autoantibody specificities 
are secreted by NZB B-1 splenic cells (13). Autoantibodies 
to BrMRBC are secreted by splenic and peritoneal B-1 cells 
1 Abbreviations  used in  this paper: B6, C57BL/6;  B6/Ipr,  C57BL/6-1pr/ 
Ipr; B6//pr-lgh% C57BL/6-1pr/Ipr-Igh';  B6-Thy-l.1, B6.H.-Thy-IVCy; 
BrMR.BC, bromdain-treated  mouse red blood  cells; EDF, equivalent 
dilution factor; FALS, forward angle light scatter; IgH, immunoglobulin 
heavy chain; MRL/~r, MILL-MpJ-~r/I/m  PenStr~, penidllin streptomycin; 
PerC, peritoneal washout cells; ssDNA,  single stranded DNA. 
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Coombs autoantibody transgenes have provided the first di- 
rect evidence that B-1 cells can produce potentially patho- 
genic autoantibodies in vivo (18). 
Mice homozygous for the autosomal recessive gene Ipr, 
recently demonstrated to code for a  mutant form of the 
apoptosis-inducing surface receptor,  Fas (19), develop gener- 
alized lymphoproliferation (20).  They also produce a spec- 
trum of autoreactivity that resembles  that found in human 
SLE. Whether their autoantibodies are produced by a dis- 
crete B cell subset is unknown. In the current studies, we 
have investigated the role of B-1 cells in SLE-like systemic 
autoimmunity in Igh allotype-congenic lpr mouse strains. 
Taking advantage of the capability of B-1 cells to self-renew 
after transfer in vivo (6),  we prepared double chimeric Ipr 
mice in which B-1 and conventional B cells and their anti- 
body products could be readily distinguished using aUotype- 
specific reagents. We found that the autoantibodies were pro- 
duced almost entirely by bone marrow-derived conventional 
B cells. Furthermore, there was an unexpected age-related 
disappearance of peritoneal B-1 cells both in Ipr chimeras and 
in unmanipulated Ipr mice. 
Materials and Methods 
M~  C57BL/6 036), B6.C20, C57BL/6-1pr/lpr (B6/lpr), B6.PD 
Thy-P/Cy (B6-Thy-l.1), and C57BL/6-1pr/lpr-Igh ~ (B6/Ipr-Igh') 
mice were raised in our breeding colony. The B6/Ipr strain was 
originally  obtained  from The Jackson Laboratory  (Bar Harbor, ME), 
and the B6/Ipr-Igh ~ strain was developed in our laboratory by 
crossing B6.C20 (obtained from Dr. Gayle Bosma, Institute for 
Cancer Research, Philadelphia, PA) and B6/Ipr. By 5 mo of age, 
the B6/Ipr-Igh  ~ mice develop autoantibodies to chromatin and to 
IgG, lymphadenopathy,  and splenomegaly  (21). Mice used for peri- 
toneal cell donors were 4-8-wk-old. Bone marrow donors were 
6-10-wk-old, and recipients for irradiation chimeras  were 6-8-wk- 
old. Animals of one sex were used in individual experiments. 
Preparation of Cells.  Femurs  and tibias were used as sources of 
bone marrow cells. Cold medium (RPMI 1640 with 15 mM Hepes, 
100 U/m1 penicillin, and 100/~g/ml streptomycin (PenStrep) from 
the University of North Carolina Cancer Center Tissue Culture 
Facility)  was injected  into the marrow cavity,  and ceils  were washed 
three times. Peritoneal washout ceils (PerC) were obtained by in- 
jecting 4-6 ml of chilled media containing 10% newborn calf sera 
into the peritoneal cavity.  The recovered  cells, ,x,60% lymphocytes, 
were washed twice with serum-free medium. 
Preparation of Radiation Chimeras.  1 wk before cell transfer, 
recipients and donors were bled. Recipients were moved to au- 
toclaved cages in an isolation cubicle, and water was treated with 
neomycin (0.2% wt/vol). 1 d before transfer, mice received 750 
rad  of gamma-radiation in  a  137Cs gamma  cell 40  apparatus 
(Atomic Energy of Canada, Ltd., Ottawa, Canada) or from a s~7,o 
source (Atomic Energy of Canada, Ltd.). Ceils were resuspended 
in serum-free  medium, and 107 bone marrow cells mixed with 107 
PerC were injected into the tail vein of irradiated recipients (6). 
Neonatal Chimeras.  B6/Ipr mice were injected within 1 d of 
birth with 0.1 mg of anti-IgM  b mAb (AF6-78.25), followed by 
twice weekly injections of 0.2 mg for 1 too. On day 2 or 3 after 
birth,  treated mice were injected intraperitoneally with 3  x  10  ~ 
PerC from 4-8-wk-old B6/lpr-Igh a donors (22, 23). 
Antibodies.  Anti-Igh-6b (anti-IgMb; AF6-78.25, mouse IgG1) 
was obtained from Dr. A. Stall (Columbia University, New York) 
(24) and was purified from mouse ascites by 50% ammonium sul- 
fate precipitation for neonatal injections. For immunofluorescence, 
the antibody was further purified over a protein G column (Genex, 
Gaithersburg, MD), or a directly fluoresceinated  preparation was 
used (PharMingen,  San  Diego,  CA).  Anti-Igh-5a  (anti-IgD~; 
HSa/1,  mouse  IgG2b) was  obtained  from  Dr.  F.  Finkelman 
(Uniformed  Services, University  of  Health Sdences, Bethesda, MD) 
(25). Anti-Igh-5b (anti-IgDb; AF3.33.3.2, mouse IgG2a) was ob- 
tained from Dr. V. Oi (Becton Dickinson & Co., Mountain View, 
CA) (24). Anti-Ly-1  (anti-CD5; 53-7.313, rat IgG2a) was obtained 
from Dr. G. Haughton (University  of North Carolina, Chapel Hill, 
NC) (26) and purified  from serum-free  culture supernatant (HB102; 
New England Nudear Research Products, Boston, MA). Fluorescei- 
hated anti-Igh-6a (anti-IgMa; DS-1, mouse IgG1) was from Phar- 
Mingen (27). Cell lines for anti-Fc-'y receptor antibody (2.4G2, 
rat IgG2b) and anti-Mac-1 (M1/70.15.11.5.HL, rat IgG2b) were 
obtained from American  Type  Culture Collection (Rockville, MD) 
(28, 29). Anti-IL-5 receptor antibody (R52.120, rat IgG1) was a 
gift from Dr. R. Palacios (Basel Institute for Immunology, Basel, 
Switzerland) (30), and biotinylated anti-CD23/IgE  FcR (B3B4, 
rat IgG2a), was a gift from Dr. T. Waldschmidt (University of 
Iowa, College of Medicine, Iowa City, IA) (31). Biotinylated anti- 
CD45R/B220  (RA3-6B2,  rat IgG2a) was obtained from Phar- 
Mingen (32). 
Iramunofluorescence.  Aliotype-specific  two-color flow  cytometric 
analysis of IgD  ~  vs. IgM', IgD  b vs. IgM  b, CD5 vs. IgM  b, and CD5 
vs. IgM  ~  was routinely performed on peritoneal cells and splenic 
lymphocytes  at the time of  kiUing. PerC were obtained as described 
above. Splenic  lymphocytes  were isolated by disrupting the splenic 
capsule between frosted ends of  glass slides  and washing twice with 
RPMI 1640 supplemented  with 3% FCS, Hepes, 0.1% NAN3, and 
PenStrep. Erythrocytes  in spleen and peritoneal  ceils  were lysed  with 
ammonium chloride for 5 rain at 4~  All samples were treated 
with anti-Fc-"/receptor antibody for 20 rain at 4~  to block any 
nonspecific  binding. For the allotype-specific  IgM vs. IgD staining 
of the a allotype, fluoresceinated DS-1, and biotinylated HSffl 
were added for 30 min at 4~  The cells were washed three times 
between steps, PE-coupled  avidin (Fisher Scientific  Co., Pittsburgh, 
PA) was added, and the cells were incubated on ice for 30 min. 
They were washed once in staining medium and twice in PBS and 
fixed with an equal mixture of PBS and 2% paraformaldehyde  in 
PBS. The IgM vs. IgD staining for the b allotype was essentially 
the  same except fluoresceinated AF6-78.25 and  biotinylated 
AF3-33.3.2 were added for the first step. For the CD5 vs. IgM  ~ 
or IgM  b staining, biotinylated 53.7.313 was added along with the 
allotype-specific  fluoresceinated  anti-IgM reagents described  above. 
After washing, PE-coupled avidin was added, and the procedure 
was continued as described above. Two-color analysis with bio- 
tinylated anti-Mac-1 or anti-IL-5R and  allotype-specific  FITC- 
conjugated anti-IgM reagents was performed on some samples to 
confirm B-1 cell staining. For each assay, age-matched  B6, B6.C20, 
B6/Ipr,  and B6/Ipr-Igh a splenic lymphocytes and PerC were pre- 
pared as controls. Analysis  was performed  on a flow cytometer  (Epics 
V; Coulter Electronics, Hialeah, FL) with size gating on the lym- 
phocyte population. B-1 and conventional B cell populations were 
defined by gates set on the control samples in each experiment. 
In most cases, backgating was performed on the two-color histo- 
grams for size and granularity analysis to confirm staining of the 
B-1 cell population. Initially, cells were also stained with isotype- 
matched biotinylated anti-Ly-2  (53-6.72, rat IgG2a [26]), obtained 
from Dr. L. Arnold (University of North Carolina, Chapel Hill, 
NC) to establish specificity  of  the anti-CD5 antibody reagent. Data 
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angle vs. 90  ~ light scatter, which is linear. 20,000 events were col- 
lected per sample in most experiments. 
ELISA.  Allotype-specific  total serum IgG2a and IgM, IgM 
R.F, IgM and IgG2a anti-ssDNA, and IgG2a antichromatin were 
measured as previously  described (21). RF and IgG2a anti-ssDNA 
concentrations were expressed  in equivalent  dilution factors (EDF), 
defined by the formula: EDF  =  (Dilution of standard reference 
sen which gives the equivalent OD of the test serum) x  106 (21). 
Results 
Conventional B Cells Were Responsible for Autoantibody Produc- 
tion  in  Ipr Irradiation  Chimeras.  Equal numbers of B6/Ipr 
(Igh  b) bone marrow cells  and B6/Ipr-Igh"  peritoneal calls 
were transferred to irradiated (750 R) B6/Ipr recipients (ir- 
radiation chimera I, Table 1). In this model, the bone marrow 
donor should reconstitute the conventional B cell subset, and 
the peritoneal ceUs should reconstitute the B-1 subset (6). 
Adequate chimerism was established by 3 mo after transfer, 
as both a  and b allotypes significantly contributed to total 
serum IgM (Table 2). B-1 cells (a allotype) made only a minor 
contribution to total IgG2a. Two-color flow cytometry  showed 
that virtually all B ceUs in the peripheral blood were derived 
from the bone marrow (data not shown).  All of the an- 
tichromatin autoantibody at 3 mo was from the conventional 
(b allotype) B cell source,  as well as most of the IgM RF 
(Table 2). At 5 mo after transfer,  B-1 cells still contributed 
significantly to total serum IgM, but essentially all of the 
autoantibodies came from the conventional B cells. 
A reciprocal set of  irradiation chimeras gave similar results. 
Irradiated  B6/Ipr-Igh*  mice  received  B6/lpr-Igh a  bone 
marrow and B6//pr peritoneal cells (irradiation chimera II, Table 
Table  1.  Chimeras Established to Determine the Role of B-1  Cells in Autoantibody  Production in Ipr Mice 
Conventional B Cell 
Chimera  Type  Host  Call Transfer  Allotype  B-1 Call Allotype  Fas 
I  Irradiation  B6/lpr  B6/Ipr bone marrow  and  b  a  lpr 
B6/lpr-Igh"  peritoneal calls 
II  Irradiation  B6/lpr-Igh"  B6/lpr-Igh' bone marrow  and  a  b  Ipr 
B6/Ipr peritoneal cells 
Ill  Neonatal  B6/Ipr  B6/lpr-Igh"  peritoneal cells  b  a  lpr 
IV  Irradiation  B6  B6 bone marrow  and B6.C20  b  a  + 
peritoneal calls 
V  Irradiation  B6.C20  B6.C20 bone marrow and B6  a  b  + 
peritoneal cells 
VI  Neonatal  B6  B6.C20 peritoneal calls  b  a  + 
VII  Irradiation  B6/Ipr-Igh ~  B6/lpr-Igh a bone marrow  and  a and b  a and b  +  and Ipr 
peritoneal cells and B6-Thyl.1 
bone marrow and peritoneal ceils 
Table  2.  Conventional, Bone Marrow-derived B  Cells Produced Autoantibodies in Chimera I* 
Serum Ig  Antichromatin 
Age after transfer  IgM'  IgM  b  IgG2a"  IgG2a  b  IgG2a*  IgG2a  b 
Serum autoantibody 
RF specificity 
IgGI*(EDF)  IgG2bb(EDF) 
IgM'  IgM  b  IgM*  IgM  b 
~g/ml 
3 mo (16)*  840(78)S  206(57)  47(8)  495(24) 
5 mo (16)  509(106)  886(35)  35(10)  3,000(260) 
ng/ml 
_  II  516(59)  18(5)  105(42)  28(9)  238(38) 
_  II  8,672(4,845)  10(7)  96(27)  9(2)  97(24) 
" B6/lpr bone marrow and B6/Ipr-Igh* peritoneal cells were transferred into irradiated B6/lpr recipients. 
* Number of animals tested. 
S  Data represent means (SE) of ELISA results. 
n Below lower limits of detection of assay, i.e., <37 ng/ml. 
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Serum Ig  Antichromatin 
Age after transfer  IgM  ~  IgM  b  IgG2a  ~  IgG2a  b  IgG2a'  IgG2a  b 
Serum autoantibody 
RF  specificity 
IgGI'(EDF)  IgG2bb(EDF) 
IgM"  IgM  b  IgM'  IgM  b 
/~g/ml  ng/ml 
2 mo (4)*  325(50)S  380(60)  2,960(831)  156(53) 1,627(654)  _ II  _'1 
3 mo (7)  1,300(440)  370(60)  2,385(433)  150(60) 6,807(2,517)  _11  30(25) 
-'"  28(18)  -'" 
-'*  40(12)  -** 
* B6/Ipr-IgD bone marrow and B6/Ipr peritoneal cells were transferred into irradiated B6/Ipr-Igh, recipients. 
* Number of animals tested. 
S  Data represent means (SE) of ELISA results. 
N  Below lower limits of detection of assay, i.e., <32 ng/ml. 
Below lower limits of detection of assay, i.e.,  <5 EDF. 
** Below lower limits of detection of assay, i.e.,  <3 EDF. 
1). Chimerism was established by 2 mo after transfer, as shown 
by quantitation of IgM of the a  and b allotypes (Table 3). 
A minor contribution by the B-1 cells to total serum IgG2a 
was seen. The allotype distribution of autoantibodies mea- 
sured 2 and 3 mo after transfer indicated that conventional 
B cells (a allotype) were responsible for the specificities as- 
sayed (Table 3).  In this set of chimeras, consistent with the 
previous experiment, the B-1 cells (b allotype) made no con- 
tribution  to antichromatin or RF. 
Peritoneal Cell Populations in lpr Irradiation Chimeras Did Not 
Show Porsistence of  B-1 Cells.  In B6 and B6.C20 control mice, 
CD5-bearing  peritoneal  B-1  (subset  B-la)  cells  were  first 
identified by double staining for CD5  and IgM (Fig.  1 A, 
top). This population is also IgM~IgD  l~  as is the CD5-  B-1 
(subset B-lb) "sister population" (Fig. 1 A, bottom) (14,  22, 
23).  B6  mice  averaged  25%0 CD5+IgM +  and  33%  Ig- 
MhiIgD  1~ peritoneal B-1 cells (n  --  5;  age, 3 too).  Control 
mice of the a  allotype, B6.C20,  showed 33%  CD5 +  IgM +, 
and  55%  IgMhiIgDl~ B-1  peritoneal  ceils  (n  =  5;  age, 
3 mo).  In contrast,  however, peritoneal cells from a repre- 
sentative irradiation chimera I (B6/lpr host), killed 5 mo after 
transfer,  showed no B-1  cells of either allotype (Fig.  1 B). 
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Figure 1.  Lpr chimeras  had few peritoneal  B-1 cells. 
Rqn'esentative  data  for two-color  flow  cytometric  anal- 
ysis  of  peritoneal  cells stained  with anti-CD5 and ap- 
propriate allotypic markers for unmanipulated  con- 
trol mice (,4), and chimeras killed 5 mo after cell 
transfer (B-D) are shown. B-1 cells are identified  by 
the indicated gates. R~r to Table 1 for description 
of chimeras. Table  4.  Conventional, Bone Marrow-derived B Cells Produced Autoantibodies in Chimera lip 
Serum Ig 
Serum autoantibody 
RF specificity 
Antichromatin  IgGP(EDF)  IgG2bb(EDF) 
IgG2a  b  IgM'  IgM  b  IgM'  IgM  b  Age after transfer  IgM"  IgM  b  IgG2a"  IgG2a  b  IgG2# 
/~g/ml 
5 wk (12),  217(44)s  _  II  29(19)  123(13) 
2 mo (.)  698(87)  590(67)  81(12)  1,536(1,180) 
4 mo (12)  421(56)  2,850(180)  _ n  5,048(2,210) 
5 mo (5)  84(15)  3,000(200)  82(43)  8,706(2,780) 
ng/ml 
ND  ND  ND  ND  ND  ND 
-  '  309(100)  -  **  15(6)  5(1)  16(4) 
_I  12,900(6,770)  -**  216(22)  -**  127(20) 
-~  6,741(3,400)  -**  182(33)  -**  117(20) 
* B6/Ipr-Igh" peritoneal cells were transferred into anti-IgMb-treated B6/lpr neonatal recipients. 
* Number of animals tested. 
S  Means (SE) of ELISA results. 
n Below ~htection of assay i.e., <29/zg/ml. 
￿82  Below lower limits of detection of assay, i.e., <37 ng/ml. 
** Below lower limits of detection of assay, i.e., <5 EDF. 
Similarly,  peritoneal ceils from a representative irradiation chi- 
mera II (B6/Ipr-Igh a host) killed 5 mo after transfer showed 
few B-1 ceils of either aUotype by both criteria used to iden- 
tify B-1 cells (Fig.  1 C). 
Neonatal  Chimeras  Paralleled the Remits  of the Irradiation 
Chimeras.  In a second approach to establish B cell chimeras 
(22, 23), neonatal B6/lpr mice were treated with anti-IgM  b 
and injected with B6/Ipr-Igh"  peritoneal cells from young 
adults (neonatal chimera III, Table 1). In this model, the in- 
jected antibody suppresses host B cells. The conventional B 
cells recover after the treatment is stopped, and the B-1 cell 
subset is reconstituted by the injected peritoneal population 
(22,  23).  Suppression of the host IgM-bearing  neonatal B 
calls by anti-IgM b was successful,  as assayed by ELISA at 
5 wk of age (Table 4). At 2 mo, both B-1 and conventional 
B  ceils contributed to total serum IgM, but thereafter the 
contribution of the B-1 ceils (a ailotype) decreased. The IgG2a 
antichromatin  and  IgM  RF  directed  against  IgG1 '  and 
IgG2b  b were made  exclusively by the  b allotype,  conven- 
tional B cells  at all time points (Table 4).  Two-color flow 
cytometric analysis  demonstrated  that  the B-1 cell popula- 
tion was nearly absent from the peritoneal cavity 3 mo after 
transfer (Fig. 1 D). Subsequent killing at 8 mo after transfer 
showed that  B-1 cells did not return  (data not  shown). 
Conventional B Cells Produced lgM and lgG2a ssDNA in All 
Ipr Chimeras.  Since B-1 cells were previously reported to se- 
crete authoantibodies specific for ssDNA (13),  sera from Ipr 
chimeras were assayed for IgM and IgG2a anti-ssDNA (Table 
5). In all cases, these autoantibodies were made only by con- 
ventional B cells. 
Normal Chimeric Mice Demonstrated Persistence of the 13-1 Cells 
After Transfer.  When chimeric mice were set up using normal 
congenic mouse strains in the same way as I/n" strains described 
above, transferred peritoneal cells were found to reconstitute 
a persistent B-1 lineage,  as has been reported (6, 9, 22, 23, 
33). Shown in Fig. 2 are representative flow cytometric anal- 
Table  5.  Conventional, Bone Marrow-derived B Cells Produced Anti-ssDNA  Autoantibodies in Ipr Chimeras* 
OD  EDF 
Chimera  IgM'  IgM  b  IgG2a"  IgG2a  b 
Irradiation  I  (10)*  0H(0)s  .14(.06)  0(0)  18(13) 
Irradiation  II (8)  .06(.02)  .01(.01)  7.6(3.4)  .04(.03) 
Neonatal III (12)  .03(0)  .24(.07)  .08(.03)  43(22) 
* Kefer to Table 1 for description of chimeras; data obtained from bleeds done 4-5 mo after transfer. 
* Number of mice. 
S Mean (SE). 
Data for B-1 cells are in bold. 
73  Reap et al. Figure 2.  Normal chimeras had significantly more B-1 cells of the trans- 
ferred allotype than lpr chimeras. Peritoneal cells stained for B-1 cells using 
CD5 and IgM allotypic markers are shown from representative chimeras 
killed 4--6 mo after cell transfer. B-1 cells are outlined in the gates. Refer 
to Table 1 for description of chimeras. 
yses of each type of normal chimera (Types IV-VI,  Table 1) 
killed at ',~4-6 mo after transfer,  and stained for CD5 and 
IgM.  Double staining with IgD and IgM showed higher 
numbers of B-1 cells (data not shown). The transferred B-1 
cells also were persistently functional in all three types of 
normal chimeras, as evidenced by their contribution to total 
serum IgM at 3-5 mo after transfer  (Table 6). 
Intact B6/Ipr and B6/Ipr-Igl~ Mice Showed a Loss of Perito- 
heal B-1 Cells with Time.  The chimera results raised the pos- 
sibility that Ipr mice might undergo spontaneous loss of B-1 
cells with time. Unmanipulated lpr and control mice were 
therefore stained for B-1 cells at different ages. Figs. 3 and 
4  show  that  B6/lpr  and  B6/lpr-Igh"  mice  had  an  age- 
associated  decrease  in  the  proportion of B-1  cells  in  the 
peritoneum, when compared with age- and allotype-matched 
normal congenic B6 and B6.C20 controls. Shown in Fig. 4 
are peritoneal cells from a 4-mo Ipr, a 2-too Ipr, and a 2-mo 
control mouse. Lpr mice of the approximate age previously 
used as peritoneal cell donors (2-mo-old) had a normal popu- 
lation of B-1 cells. However,  a relative decrease in the B-1 
cell population  was apparent already in the 4-too-old lpr mouse. 
Even fewer B-1 cells could be identified in the peritoneum 
Figure 3. 
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Lpr mice showed a decrease in B-1 peritoneal cells with age. 
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Age-matched B6/Ipr. B6/Ipr-Igh  a, and control B6 and B6.C20 mice were 
analyzed by flow cytometry for B-1 cells in the peritoneal cavity  by double 
staining for IgM and CD5. Data represent an average of 3-5 mice per 
time point  _+  SE. ([]) B6;  (,)  B6/Ipr; (O) B6.C20;  (@) B6/Ipr-lgh=. 
of 8-mo-old unmanipulated Ipr mice using four additional 
markers (IL-5R, Mac-l, B22(F  ~  and absence/low expression 
of CD23) for B-1 cells in conjunction with anti-IgM (Fig. 
5) (34,  35).  The small population of cells defined by anti- 
CD23 and IL-5R in the Ipr mouse within the B-1 gates (Fig. 
5) may represent activated conventional B celts (34, 35). Shown 
also is the forward angle light scatter vs. linear 90  ~ scatter, 
since B-1 calls have increased forward angle and 90  ~ scatter. 
The age-related relative decrease in peritoneal B-1 cells in 
Ipr mice shown in Figs. 3-5 reflects a comparable absolute 
diminution of this population. For example, in the animals 
from whom the data in Fig. 5 were obtained, 5,000 perito- 
neal B-1 cells were recovered from the lpr mice, compared 
with 900,000 from the normal one. In contrast, both Ipr and 
normal 2-mo-old animals,  such as the ones shown in Fig. 
4, had •250,000  peritoneal B-1 cells. In general, the total 
number of calls recovered from the peritoneal washouts of 
Ipr mice did not differ systematically from what we obtained 
from normal mice, although there was a high degree of in- 
dividual variability. The conventional B cells also decreased 
with age in Ipr peritoneal populations, but to a much lesser 
degree (data not shown). Thus the apparent loss of B-1 cells 
in the Ipr strain was not merely due to dilution by the expan- 
sion of other cell populations. 
Table  6.  B-I  Cells Are Present at 3-5 mo after  Transfer in  Chimeras  Using Normal Congenic Strains of Mice" 
Serum  lg 
Chimera  No.  mice  IgM'  IgM  b  IgG2a'  IgG2a  b 
~g/ml 
Irradiation IV  2  585(15)*  365(35)  31(19)  2,200(300) 
Irradiation V  5  598(100)  352(47)  3,200(1,400)  42(17) 
Neonatal VI  5  490(140)  486(106)  0  2,400(370) 
* Refer to Table 1 for description of chimeras;  data obtained from chimeras  3-5  mo after transfer.  Data for B-1 cells are in bold. 
* Mean (SE). 
74  B Cell Subsets in lpr Mice Figure 4.  The Ipr peritoneal B-1 cell population decreased with age. 
2-too-old B6.C20  and B6/Ipr-Igh*,  and 4-too-old B6/l/,r-lgh' peritoneal 
washouts were stained with appropriate reagents to delineate B-1 cell popu- 
lations. 
The lpr Peritoneal Environment Was Not Able to Support De- 
velopment of Normal B-I  Cells.  To investigate whether the 
loss of Ipr B-1 cells was due to an intrinsic defect in the Ipr 
B-1 cells, chimeras were created in which normal B-1 ceUs 
were transferred into an lpr environment. Equal numbers of 
B6/Ipr-Igh a and B6-Thy-l.1  bone  marrow and  peritoneal 
ceils were transferred  into  irradiated  (750 K)  B6/Ipr-Igh a 
recipients (irradiation chimera VII,  Table 1). No B-1 calls of 
the normal b allotype (B6-Thy-l.1) and few B-1 cells of the 
lpr a  allotype  (B6/lpr-Igh ~) were found in  the peritoneal 
cavity 3 mo after transfer (Fig. 6). Five chimeras killed 1-3 
mo after transfer averaged 0% b allotype normal B-1 cells, 
and 3% a allotype  Ipr B-1 cells. 
Discussion 
Our results demonstrate that B-1 cells were not respon- 
sible for producing autoantibodies to chromatin, ssDNA, and 
IgG in Ipr mice. Two different methods were used to make 
B call chimeras, such that B-1 and conventional B cell subsets 
were differentially marked by allotype. In all situations, we 
found that the conventional  B cells were nearly entirely respon- 
sible for producing the autoantibodies measured. As autoan- 
tibody and Ig production by the conventional B cells increased 
with age, B-1 cell contribution to IgM decreased or remained 
constant. The occasional small contribution to RF from B-1 
cells at two mo after transfer decreased further with time. 
B-1 cells in the peritoneal cavity were substantially depleted 
in all types of Ipr chimeric mice 5 mo after transfer. Our data 
also showed a time-dependent  loss of B-1 cells in unmanipu- 
luted Ipr mice. 
Certain evidence  had already suggested that B-1 cells might 
not be involved in autoimmunity in Ipr mice and related 
models. Monoreactive, high affinity autoantibodies,  gener- 
ally IgG, are produced by the conventional subset, and low 
affinity, generally IgM polyreactive autoantibodies come from 
the B-1 subset (36, 37). Autoantibodies  characteristic of Ipr 
systemic autoimmunity are in most cases IgG and undergo 
extensive  somatic mutation and addition of  N regions (38-40). 
Autoantibodies produced by the B-1 cells, in contrast, gener- 
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Figure 5.  Failure to detect B-1 cells in old Ipr mice. 8-mo-old control 
B6.C20  (left)  and age-matched B6//pr-lgh~  (right)  peritoneal cells were 
stained for B-1 cells with mAbs specific for CD5, IgD', IL-SK, Mac-l, 
CD23,  B220,  and IgM,.  (Bottom)  Linear 90 ~ light scatter vs. forward 
angle light scatter (FALS). B-1 cells are outlined for each stain by the gates 
shown. 
ally do not have somatic mutations or N regions (3, 15). Fur- 
thermore, irradiated Ipr mice reconstituted with autologous 
marrow generate high titers of autoantibodies  (21), despite 
the fact that B-1 cells are thought not to originate from adult 
marrow. The numbers of  splenic  B-1 cells  in MRL/MpJ-lpr/Ipr 
(MRL/Ipr) mice were not found to be increased (8). In addi- 
tion, autoantibodies (nonpathogenic) characteristic of the B-1 
cell subset have previously been shown to decrease in un- 
manipulated  MRL/lpr  mice (41). 
In contrast to these studies, a recent paper showed that 
transgenic mice carrying genes encoding antierythrocyte  an- Figure 6.  Normal B-1 cells, represented by b allotype, did not persist 
in peritoneal cavities of Ipr mice. A representative chimera VII killed 3 mo 
after cell transfer is shown. The peritoneal cells were stained with reagents 
to identify B-1 cells, which are outlined in the gates shown for each stain. 
Refer to Table 1 for description of chimera. 
tibodies had B-1 cells that apparently produced pathogenic 
autoantibodies (18). Although this model points to the di- 
rect involvement of B-1 cells in autoimmune disease, the trans- 
genes encoded IgG anti-self antibodies that are not typical 
orB-1 cells. These autoantibody-producing B-1 cells may thus 
not exist naturally and may therefore represent disease-causing 
cells only in these special circumstances. Also, the model em- 
ployed and the specificity of  autoantibodies  were different from 
those studied in the present report.  In other experiments, 
a  10-100-fold increase in  the B-l-related specificities  anti- 
BrMRBC  and anti-T cell was seen, again using a different 
technique and measuring different specificities than we em- 
ployed in the present studies (42).  An alternative possibility 
to implicate B-1 cells in the pathogenesis of disease was sug- 
gested by Shirai et al.  (43).  These investigators postulated 
that IgM B-1 cells in autoimmune NZB mice and related strains 
switch to pathogenic autoantibody producing cells and lose 
their CD5 antigen. This scenario, however, can be ruled out 
in our chimeras, since allotype marked cells were used. 
The age-associated disappearance in Ipr mice of peritoneal 
B-1 cells, seen in chimeras and in unmanipulated mice, is con- 
sistent with the lack of significant contribution to autoanti- 
body production by this subset. On the other hand, in the 
irradiation chimeras (chimeras I and II) but not the neonatal 
chimera (chimera III), B-1 cells must have persisted some- 
where, since their contribution to serum IgM was relatively 
stable. The failure of lpr B-1 cells to produce autoantibodies 
thus cannot be entirely a result of their disappearance from 
the peritoneum, but rather also implies a basic inability of 
this  subset to participate in the lpr  syndrome. 
The loss of peritoneal B-1 cells could be due to several  mech- 
anisms.  We did not find a massive increase in other perito- 
neal cell populations in Ipr mice, so a trivial dilution effect 
cannot be the major explanation. Our experiments with the 
cotransfer of normal B-1 cells into an lpr environment point 
to an extrinsic influence rather than an intrinsic Ipr B-1 cell 
defect. The lpr T cells could thus suppress  the B-1 cells. Al- 
ternatively, the regulation of the B-1  cells could be under 
the control of the conventional lpr B cell. Recently, the dis- 
appearance of B-1  cells  after treatment with  anti-Ibl0  in 
normal mice was shown to be due to increases in "y-interferon, 
since cotreatment with anti-~/-interferon prevented B-1 cell 
loss (44). We are investigating these as possible mechanisms 
for loss of B-1 cells in Ipr mice, particularly since some au- 
toimmune strains have increased levels of qc-interferon  (45). 
SJL is another mouse strain in which a deficit of B-1 cells 
correlates with autoimmunity. SJL mice do not produce anti- 
BrMRBC plaque-forming cells in vitro (46), and phenotypic 
B-1 cells represent only 1-5% of their peritoneal cells (47). 
Furthermore, the SJL strain is unusually susceptible to the 
induction of certain autoimmune diseases, such as experimental 
autoimmune encephalomyelitis (48). 
It is tempting, therefore, to speculate that B-1 cells may 
play some role in maintaining homeostasis of the organism 
and that the loss of B-1 cells in Ipr mice might in fact con- 
tribute to the autoimmune syndrome. Since B-1  cells have 
been deemed important in idiotypic networks and B cell on- 
togeny, and because they are increased in neonates (10, 49, 
50), the disappearance of B-1 cells could disrupt the network 
and release autoreactive clones that are normally held in check 
by idiotypic-antiidiotypic interactions. It was also recently 
found that B-1 cells are important producers of  11,10, a cytokine 
that  inhibits  production  of several  T  cell  cytokines  and 
monokines (51). Previously, it has been shown that certain 
B-1 cells produce a helper B cell factor, assigning an addi- 
tional regulatory function to this subset (52).  B-1 cells may 
thus participate in the immune response as active, regulatory 
cells (53-57), and may not merely represent a vestigial subset 
of a more primitive, first line defense. B-1 cells themselves, 
however, are not responsible for autoantibody production in 
lpr mice. 
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